{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:42:56Z","timestamp":1793727776437,"version":"4.6.1"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Posdinemab, a humanized immunoglobulin G1\/\u03ba monoclonal antibody, binds with high affinity to phosphorylated tau protein which is associated with Alzheimer's disease (AD) pathophysiology. Posdinemab reduced tau seeding in murine models and was well tolerated in Phase\u20101 clinical studies. This open\u2010label, single\u2010arm, Phase\u20101 study examined the effects of posdinemab with single intravenous dose (60 mg\/kg) in healthy adults from China. The main objectives were to assess posdinemab serum pharmacokinetics (PK, primary), safety and tolerability (secondary), and presence of anti\u2010drug antibodies (ADAs; secondary). Results were compared with Phase\u20101 European first\u2010in\u2010human (NCT03375697) and Japanese (NCT03689153) studies. Healthy Chinese participants (N = 10), mean age 60.0 (SD 3.80) years and 60% female, received posdinemab. Mean posdinemab serum C\n                    <jats:sub>max<\/jats:sub>\n                    was 1401 \u00b5g\/mL, median t\n                    <jats:sub>max<\/jats:sub>\n                    was 0.08 days, mean AUC\n                    <jats:sub>inf<\/jats:sub>\n                    was 18162 \u00b5g\u00b7day\/mL, mean CL was 3.36 mL\/day\/kg, and mean elimination t\n                    <jats:sub>1\/2<\/jats:sub>\n                    was 17.5 days. Most participants (n = 8; 80%) experienced \u22651 treatment\u2010emergent adverse event (TEAEs), most common (20%) of which were arthralgia and back pain. Four participants (40.0%) were positive for posdinemab ADAs post\u2010dose with peak titers of 1:22.5 (n = 3) and 1:360 (n = 1). Serum posdinemab concentrations in ADA\u2010positive and ADA\u2010negative participants were generally comparable. In conclusion, PK profile of posdinemab in healthy participants from China was in the expected range and comparable to previous Phase\u20101 studies in Europe and Japan. There were no new safety concerns. These results support further global development of posdinemab in AD.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70116","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:21:04Z","timestamp":1760404864000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Posdinemab (JNJ\u201063733657) in Healthy Chinese Adults"],"prefix":"10.1002","volume":"66","author":[{"given":"Fangfang","family":"Wang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine Peking University Third Hospital  Beijing China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular\u2010Kidney\u2010Metabolic and Immuno\u2010Inflammatory Innovative Drugs and Medical Devices Peking University Third Hospital  Beijing China"},{"name":"Drug Clinical Trial Center, Department of Pharmacy Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juanfang","family":"Liu","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisy","family":"Bai","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingjue","family":"Li","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Fedgchin","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Henley","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Titusville NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Cardiology and Institute of Vascular Medicine Peking University Third Hospital  Beijing China"},{"name":"Beijing Key Laboratory of Clinical Evaluation of Cardiovascular\u2010Kidney\u2010Metabolic and Immuno\u2010Inflammatory Innovative Drugs and Medical Devices Peking University Third Hospital  Beijing China"},{"name":"Drug Clinical Trial Center, Department of Pharmacy Peking University Third Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.23"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00269-y"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.226389"},{"issue":"03","key":"e_1_2_11_5_1","first-page":"219","article-title":"China Alzheimer report 2024","volume":"23","author":"Wang G","year":"2024","journal-title":"Diagn Concepts Pract"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170784"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/156720510793611592"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.163"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R114.549295"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-017-0488-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0013-z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00523-w"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.1375"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2019.10.024"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz100"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep09659"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature23002"},{"issue":"11","key":"e_1_2_11_20_1","first-page":"1","article-title":"Tau\u2010targeting therapy in Alzheimer's disease: critical advances and future opportunities","volume":"2","author":"Guo Y","year":"2022","journal-title":"Ageing Neur Dis"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.074181"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.068973"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082771"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70116","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70116","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:54:03Z","timestamp":1773014043000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/jcph.70116"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70116","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"2025-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70116"}}